Prescription Drugs & Pricing
Expert articles and analysis related to prescription drugs & pricing.
AI Summary — Last 24 Hours
Synthesis:
In the past 24 hours, CMS and FDA have jointly announced a new expedited Medicare coverage pathway for FDA-designated breakthrough medical devices, aiming to accelerate beneficiary access and align coverage decisions with innovation cycles—a development with implications for population health management, ACOs, and VBC-aligned device adoption. Since this policy announcement occurred after January 20, 2025, it is a Trump administration initiative, with CMS Administrator Dr. Mehmet Oz and HHS Secretary Robert F. Kennedy Jr. overseeing the relevant agencies.
Related Articles
International Lessons on Pricing and Financing High-Cost Medicines: Policy Options for the United States
International Lessons on Pricing and Financing High-Cost Medicines: Policy Options for the United States  Commonwealth Fund
Beyond “Most Favored Nation” Drug Pricing: What the U.S. Can Learn from Other Countries
Beyond “Most Favored Nation” Drug Pricing: What the U.S. Can Learn from Other Countries  Commonwealth Fund
STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
A deal with Regeneron was the last of 17 initially sought by the White House.
STAT+: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards
Legislators in two states are resisting efforts to restrict prescription drug affordability boards.
DEA Issues Long Awaited Final Order Rescheduling Certain Marijuana Products to Schedule III: What It Means, What It Doesn’t, and What Comes Next
AMCP 2026 Spotlights New Era for Specialty Drug Market
Jeff Davis Comments on Congressional Action on 340B Reform
Jeff Davis Comments on Congressional Action on 340B Reform  Bass, Berry & Sims PLC
World Vaccine Congress Signals a Shift in Vaccine Environment
What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid  KFF
A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.